Last reviewed · How we verify

NCT06951984

Hydroxyephedrine PET/CT in Sympathetic Nervous System Disease

Recruiting now Last updated 30 April 2025
What this trial tests

trial testing 11C/18F-HED in Sympathetic Nervous System Diseases in 500 participants. Currently enrolling.

Timeline
1 March 2013
Primary endpoint
1 March 2028
1 March 2028

Quick facts

Lead sponsorTianjin Medical University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date1 March 2013
Primary completion1 March 2028
Estimated completion1 March 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Tianjin Medical University

Who can join

Adults 18 to 80, any sex, with Sympathetic Nervous System Diseases or Sympathetic Nervous Structure Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the potential usefulness of 11C/18F-HED positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tianjin Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06951984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing